3 recruiting, 1 completed, 1 not yet recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 3, Completed 1, Not yet recruiting 1 |
Follow tipiracil: new trials by email Literature Review of tipiracil trials Research Report on tipiracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI) - Metastatic Colorectal Cancer | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 1020 | 2026-05-06 | 2026-11-05 |
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets - HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 142 | 2026-03-01 | 2026-03-19 |
| A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets - Refractory Metastatic Colorectal Cancer | Phase 3 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 464 | 2025-11-12 | 2026-01-22 |
| Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer Trifluridine/Tipiracil + Regorafenib, Trifluridine/tipiracil + bevacizumab - Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 302 | 2025-04-01 | 2025-05-28 |
| Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) pembrolizumab, lenvatinib, regorafenib - Colorectal Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 563 | 2021-03-29 | 2026-02-05 |
Colorectal Neoplasms (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · EMD Serono Research & Development Institute, Inc. (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (5) · Argentina (2) · Australia (2) · Canada (2) · Denmark (2) · Germany (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · France (1)
Jing Hao, Prof. (1) · Ying Yuan, Prof. (1)
2025 (1)